Oral antidiabetic agents: Current role in type 2 diabetes mellitus

Drugs

Volumn 65, Issue 3, 2005, Pages 385-411

  Krentz, Andrew J ^a,c   Bailey, Clifford J ^b  

^a UNIVERSITY HOSPITAL SOUTHAMPTON NHS FOUNDATION TRUST   (United Kingdom)

^b ASTON UNIVERSITY   (United Kingdom)

^c SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ALLOPURINOL; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; BUFORMIN; CHLORAMPHENICOL; CHLORPROPAMIDE; FIBRIC ACID DERIVATIVE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLIQUIDONE; METFORMIN; MONOAMINE OXIDASE INHIBITOR; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PHENFORMIN; PHENYLBUTAZONE; PROBENECID; REPAGLINIDE; SALICYLIC ACID DERIVATIVE; SULFONAMIDE; SULFONYLUREA DERIVATIVE; TOLBUTAMIDE; TROGLITAZONE; UNINDEXED DRUG; VOGLIBOSE; WARFARIN;

ACUTE INTERMITTENT PORPHYRIA; ATHEROSCLEROSIS; BLOOD DYSCRASIA; BREAST FEEDING; CARDIOVASCULAR EFFECT; DIABETES CONTROL; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; ERYTHEMA MULTIFORME; FEVER; FLUSHING; HEART FAILURE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPOGLYCEMIA; HYPONATREMIA; INSULIN RESISTANCE; INSULIN TREATMENT; JAUNDICE; LACTIC ACIDOSIS; LIVER DISEASE; MICROALBUMINURIA; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OVARY POLYCYSTIC DISEASE; PATIENT COMPLIANCE; PHOTOSENSITIVITY; PREGNANCY; PROSPECTIVE STUDY; QUALITY OF LIFE; REVIEW; RISK REDUCTION; SUDDEN DEATH; UNITED KINGDOM; WEIGHT GAIN;

ALPHA-GLUCOSIDASES; BIGUANIDES; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; RANDOMIZED CONTROLLED TRIALS; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES;

STENO;

EID: 13644263258     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200565030-00005     Document Type: Review

References (75)

1. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53
2. European Diabetes Policy Group. A desktop guide to type 2 diabetes mellitus. Diabetic Med 1999; 16: 716-30
3. Tuomilheto J. Controlling glucose and blood pressure in type 2 diabetes. BMJ 2000; 321: 394-6
4. Krentz AJ, Bailey CJ. Type 2 diabetes in practice. London: Royal Society of Medicine Press, 2001
5. Adler AI. Cardiovascular risk reduction in diabetes: under-emphasized and overdue: messages from major trials. Clin Med 2001; 1: 472-7
6. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology and management. JAMA 2002; 287: 2570-81
7. Gray A, Clarke P, Farmer A, et al. Implementing intensive control of blood glucose concentration and blood pressure in type 2 diabetes in England: cost analysis. United Kingdom Prospective Diabetes Study (UKPDS) Group. BMJ 2002; 325: 860-3
8. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-93
9. Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirements for multiple therapies. JAMA 1999; 281: 2005-12
10. Evans AJ, Krentz AJ. Benefits and risks of transfer from oral antidiabetic agents to insulin in type 2 diabetes. In: Krentz AJ, editor. Drug treatment of type 2 diabetes. Auckland: Adis Books, 2000: 85-101
11. Seltzer HS. A summary of criticisms of the findings and conclusions of the University Group Diabetes Program. Diabetes 1972; 21: 976-9
12. Krentz AJ. Sulfonylureas in the prevention of vascular complications: from UKPDS to the ADVANCE study. Proceedings of the VIIIth European symposium on metabolism. Amsterdam: Elsevier Science International Congress Series 1253; 2003: 261-77
13. Evans AJ, Krentz AJ. Glimepiride: a new sulphonylurea. Prescriber 1999; 10: 51-8
14. + channels and insulin secretion: their role in health and disease. Diabetologia 1999; 42: 903-19
15. ATP channels. Biochem Soc Trans 2002; 30: 333-9
16. Rorsman P, Renstrom E. Insulin granule dynamics in pancreatic beta cells. Diabetologica 2003; 46: 1029-45
17. Groop LC. Sulfonylureas in NIDDM. Diabetes Care 1992; 15: 1737-54
18. Rendell M. The role of sulfonylureas in the management of type 2 diabetes. Drugs 2004; 64 (12): 1339-58
19. Bailey CJ, Day C. Antidiabetic drugs. Br J Cardiol 2003; 10: 128-36
20. Yki-Järvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care 2001; 24: 758-67
21. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999; 131: 281-303
22. Lebovitz HE. Insulin secretagogues: old and new. Diabetes Revs 1999; 7: 139-53
23. Krentz AJ, Ferner RE, Bailey CJ. Comparative tolerability profiles of oral antidiabetic agents. Drug Saf 1994; 11: 223-41
24. Krentz AJ, Boyle PJ, Justice K, et al. Successful treatment of severe refractory sulfonylurea-induced hypoglycemia with octreotide. Diabetes Care 1993; 16: 184-6
25. Wilson SH, Kennedy FP, Garratt KN. Optimisation of the management of patients with coronary heart disease and type 2 diabetes mellitus. Drugs Aging 2001; 18: 325-33
26. Schernthaner G, Grimaldi A, Di Mario U, et al. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest 2004; 34: 535-42
27. Landgraf R. Meglitinide analogues in the treatment of type 2 diabetes mellitus. Drugs Aging 2000; 17 (5): 411-25
28. Dornhorst A. Insulotropic meglitinide analogues. Lancet 2001; 358: 1709-15
29. Davies M. Nateglinide: better post-prandial glucose control. Prescriber 2002; 13: 17-27
30. Qiao Q, Tuomilehto J, Borch-Johnsen K. Post-challenge hyperglycaemia is associated with premature death and macrovascular complications. Diabetologia 2002; 46 Suppl. 1: M17-21
31. Lebovitz HE. α-Glucosidase inhibitors as agents in the treat ment of diabetes. Diabetes Revs 1998; 6: 132-45
32. Chiasson JL, Josse RG, Gomis R, et al. Acarbose for the prevention of diabetes mellitus: the STOP-NIDDM randomised trial. STOP-NIDDM Trial Research Group. Lancet 2002; 359: 2072-7
33. Holman RR, Cull CA, Turner RC. A randomised double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (UK Prospective Diabetes Study 44). Diabetes Care 1999; 22: 960-4
34. Chiasson J-L, Josse RG, Gomis R, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. The STOP-NIDDM Trial Research Group. JAMA 2003; 290: 486-94
35. Scheen A. Is there a role for alpha-glucosidase inhibitors in the prevention of type 2 diabetes mellitus? Drugs 2003; 63 (10): 933-51
36. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-607
37. Krentz AJ. Insulin resistance. Oxford: Blackwell Science, 2002
38. Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest 2000; 106: 453-8
39. Campbell IW. Antidiabetic drugs past and future: will improving insulin resistance benefit cardiovascular risk in type 1 diabetes mellitus? Drugs 2000; 60 (5): 1017-28
40. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996; 334: 574-9
41. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med 2002; 137: 25-33
42. Cusi K, DeFronzo RA. Metformin: a review of its metabolic effects. Diabetes Rev 1998; 6: 89-131
43. Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in the mechanism of action of metformin. J Clin Invest 2001; 108: 1167-74
44. Winder WW, Hardie DG. AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. Am J Physiol 1999; 277: E1-E10
45. Lord JM, Flight IHK, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 2003; 327: 951-5
46. Howlett HCS, Bailey CJ. A risk-benefit assessment of metformin in type 2 diabetes mellitus. In: Krentz AJ, editor. Drug treatment of type 2 diabetes. Auckland: Adis Books, 2000: 61-76
47. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-65
48. The Oxford Centre for Diabetes, Endocrinology and Metabolism: Diabetes Trials Unit. UK Prospective Diabetes Study [online]. Available from URL: http://www.dtu.ox.ac.uk/ukpds/index.html [Accessed 2004 Nov 23]
49. Hermann LS, Lindberg G, Lindblad U, et al. Efficacy, effectiveness and safety of sulphonylurea-metformin combination therapy in patients with type 2 diabetes. Diabetes Obes Metab 2002; 4: 296-304
50. Johnson JA, Majumdar SR, Simpson SH, et al. Decreased mortality associated with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 2002; 25: 2244-8
51. Diabetes Prevention Program Research Group. Reduction of the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403
52. Sulkin T, Bosman D, Krentz AJ. Contraindications to metformin therapy in patients with NIDDM. Diabetes Care 1997; 20: 925-8
53. Holt HB, Krentz AJ. Metabolic emergencies in type 2 diabetes. In: Goldstein B, Müller-Wieland D, editors. Textbook of type 2 diabetes. London: Martin Dunitz, 2003: 183-98
54. Lalau J-D, Race J-M. Metformin and lactic acidosis in diabetic humans. Diabetes Obes Metab 2000; 2: 131-7
55. Day C. Thiazolidinediones: a new class of antidiabetic drugs. Diabetic Med 1999; 16: 1-14
56. Krentz AJ, Bailey CJ, Melander A. Thiazolidinediones for type 2 diabetes. BMJ 2000; 321: 252-3
57. Rosen ED, Spiegelman BM. PPAR-γ: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 2001; 276: 37731-4
58. Fasshauer M, Paschke R. Regulation of adipocytokines and insulin resistance. Diabetologia 2003; 46: 1594-1603
59. Baldwin SJ, Clarke SE, Chenery RJ. Characterisation of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. Br J Clin Pharmacol 1999; 48: 424-32
60. Bailey CJ, Day C, Krentz AJ. Nice timing for glitazones. Br J Diabetes Vase Dis 2003; 3: 366-7
61. Buch HN, Baskar V, Barton DM, et al. Combination of insulin and thiazolidinedione therapy in massively obese patients with type 2 diabetes. Diabetic Med 2002; 19: 572-4
62. Nesto RW, Bell D, Bonow RO, el al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and the American Diabetes Association. Circulation 2003; 108: 2941-8
63. Parulkar AA, Pendergrass ML, Granda-Ayala R, et al. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med 2001; 134: 61-71
64. Yki-Järvinen H. Thiazolidinedions. N Engl J Med 2004; 351: 1106-18
65. Marten FMAC, Visseren FLJ, Lemay J, et al. Metabolic and additional vascular effects of thiazolidinediones. Drugs 2002; 62 (10): 1463-80
66. Buchanan TA, Xiang AH, Peters RK, et al. Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 2002; 51: 2796-803
67. Bell DSH. B-cell rejuvenation with thiazolidinediones. Am J Med 2003; 115(8A): 20-23S
68. Roberts AW, Thomas A, Rees A, et al. Peroxisome proliferator activated receptor-γ agonists in atherosclerosis: current evidence and future directions. Curr Opin Lipidol 2003; 14: 567-73
69. Schoonjans K, Auwerx J. Thiazolidinediones: an update. Lancet 2000; 355: 1008-10
70. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes. JAMA 2002; 287: 360-72
71. Kendall H. Trends in prescribing of drugs used to treat diabetes. Prescriber 2003; 14 (24): 38-9
72. Cuthbertson D, Leese G. Managing type 2 diabetes: oral antidiabetic drugs. Prescriber 2003; 14 (13): 47-53
73. Bell DSH. Type 2 diabetes mellitus: what is the optimal treatment regimen? Am J Med 2004; 116 (5A): 23S-9S
74. Kaufman FR. Type 2 diabetes mellitus in children and youth: a new epidemic. J Pediatr Endocrinol Metab 2002; 15 Suppl. 2: 737-44
75. Huizar JF, Gonzalez LA, Alderman J, et al. Sulfonylureas attenuate electrocardiographic ST-segment elevation during a myocardial infarction. J Am Coll Cardiol 2003; 42: 1017-21